White Paper
Conducting Research With CAR T Cells
Regulatory and Practical Considerations
Having proven successful in trials for blood cancers considered resistant or refractory to traditional treatment, CAR T is now expanding into rare diseases and nonmalignant conditions.
This white paper is an indispensable guide for research professionals looking to conduct CAR T cell studies for the first time, as well as for those seeking to expand their existing portfolio.
Some of the insights you’ll gain:
- What FDA guidance means for CAR T trials
- Facilities and infrastructure needs for participating sites
- Safety considerations for patients, staff, and others